Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2026 10:40 ET | Source: Spherix Global Insights

Eli Lilly’s Oral GLP-1 Foundayo Trails Novo Nordisk’s Wegovy Pill in Early Obesity Launch Uptake, According to Spherix Global Insights

Exton, PA, May 27, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients...
May 22, 2026 09:09 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

CHMP under (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® pill to reduce excess body weight
May 13, 2026 02:00 ET | Source: Novo Nordisk A/S

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Wegovy® pill showed 21.6% weight loss in early responders and improved mobility in OASIS-4 data at ECO2026.
May 06, 2026 01:31 ET | Source: Novo Nordisk A/S

Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026

The strong performance of Wegovy® and continued growth in International Operations have led us to raise our 2026 guidance for both adjusted sales and ...
February 05, 2026 20:51 ET | Source: Hims

Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026

Hims GLP-1 weight loss update: reported $49 compounded semaglutide pill, FDA vs. compounded distinctions, and telehealth access details for 2026